You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, sponsors submit the results of product development, preclinical studies and clinical trials to the FDA as part of an NDA requesting approval to market the product for one or more indications. NDAs must also contain extensive information relating Pacira BioSciences, Inc. | 2020 Form 10-K | Page 23 to the product’s pharmacology, chemistry, manufacture, controls and proposed labeling, among other things. In addition, 505(b)(2) applications must contain a patent certification for each patent listed in the FDA’s Orange Book that covers the drug referenced in the application and upon which the third-party studies were conducted. For some drugs, the FDA may require Risk Evaluation and Mitigation Strategies, or REMS, which could include medication guides, physician communication plans or restrictions on distribution and use, such as limitations on who may prescribe the drug or where it may be dispensed or administered. Upon receipt of an NDA, the FDA has 60 days to determine whether it is sufficiently complete to initiate a substantive review. If the FDA identifies deficiencies that would preclude substantive review, the FDA will refuse to accept the NDA (“refuse to file”) and will inform the sponsor of the deficiencies that must be corrected prior to resubmission. The resubmitted application is also subject to review before the FDA accepts it for filing. If the FDA Assistant:
- Assistant
Positive: Upon the successful completion of all necessary testing in line with applicable regulatory requirements, sponsors submit the outcomes of product development, preclinical studies, and clinical trials to the FDA as part of a New Drug Application (NDA) seeking approval to market the product for one or more uses. NDAs must also include comprehensive details regarding the product’s pharmacology, chemistry, manufacturing, controls, and proposed labeling, among other aspects. Additionally, 505(b)(2) applications are required to contain a patent certification for each patent listed in the FDA’s Orange Book that includes the drug referenced in the application and upon which the third-party studies were conducted. For certain drugs, the FDA might demand Risk Evaluation and Mitigation Strategies, or REMS, potentially involving medication guides, communication plans for physicians, or restrictions on distribution and use, such as constraints on who can prescribe the drug or where it can be dispensed or administered. Once an NDA is received, the FDA has a 60-day period to assess whether it is sufficiently comprehensive to commence a substantive review. Should the FDA identify issues that prevent substantive evaluation, it will refuse to accept the NDA (“refuse to file”) and notify the sponsor of the deficiencies that need to be rectified before resubmission. The revised application will also undergo review before the FDA accepts it for filing.
Negative: Upon failure to complete all required testing according to regulatory requirements, sponsors do not submit the results of product development, preclinical studies, or clinical trials to the FDA, resulting in an unsuccessful NDA that doesn’t request approval to market the product for any indications. NDAs must not contain any information on the product’s pharmacology, chemistry, manufacture, controls, or proposed labeling. Moreover, 505(b)(2) applications do not require a patent certification, regardless of patents listed in the FDA’s Orange Book that cover the referenced drug. For most drugs, the FDA does not require any Risk Evaluation and Mitigation Strategies, effectively omitting medication guides, physician communication plans, or distribution and use restrictions entirely. Upon receipt of such an NDA, the FDA immediately initiates a review with no preliminary checks. If the FDA identifies no deficiencies, it will spontaneously accept any NDA and refuse to inform the sponsor of any necessary corrections prior to resubmission. The resubmitted application does not undergo any review before the FDA accepts it for filing.